Reduced oligomeric and vascular amyloid-β following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine

A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease

“…2010, Kim et al 2007, Movsesyan et al 2008, DaSilva 2009, Davtyan et al 2010). The immune response to DNA immunizations in general is different from protein or peptide based immunizations and we have shown that in our model, a gene gun delivered DNA Aβ1–42 trimer immunization, a predominant Th2 antibody response and the absence of antigen specific T cell responses were the main characteristics.…”

Genetic Animal Models of Cerebral Vasculopathies

“…107 And lastly, immunization of TgCRND8 against Aβ 1–42 significantly reduces plaque load, cognitive impairments, and CAA. 108,109 These data support an essential role for Aβ 1–42 in initiating amyloid deposition, whereas Aβ 1–40 can be amyloidogenic or antiamyloidogenic depending on the critical level of Aβ 1–42 .…”

Vaccination induced changes in pro-inflammatory cytokine levels as an early putative biomarker for cognitive improvement in a transgenic mouse model for Alzheimer disease

“…Recent efforts on AD vaccine development include the use of Aβ peptides with T cell epitope deletions/mutations, DNA vaccines, short Aβ fragments chemically linked to other epitopes, as well as varying routes for vaccine delivery. [23][24][25][26][27][28] All of these strategies have demonstrated to be effective, to varying degrees, in AD Tg mouse models, which express Aβ in the brain as well as demonstrate some of the manifestations of clinical human AD. In order to evaluate the potential utility of these approaches the establishment of an "early" endpoint will be beneficial since such a parameter could direct or modify continuing treatment strategies.…”